B-intervention	0	10	Lumpectomy
I-intervention	11	15	plus
I-intervention	16	25	tamoxifen
I-intervention	26	30	with
I-intervention	31	33	or
I-intervention	34	41	without
I-intervention	42	53	irradiation
O	54	56	in
O	57	62	women
B-age	63	65	70
I-age	66	71	years
I-age	72	74	of
I-age	75	78	age
I-age	79	81	or
I-age	82	87	older
O	88	92	with
O	93	98	early
O	99	105	breast
O	106	112	cancer
O	112	113	.

O	114	116	In
O	117	122	women
O	123	125	70
O	126	131	years
O	132	134	of
O	135	138	age
O	139	141	or
O	142	147	older
O	148	151	who
O	152	156	have
O	157	162	early
O	163	169	breast
O	170	176	cancer
O	176	177	,
O	178	180	it
O	181	183	is
O	184	191	unclear
O	192	199	whether
O	200	210	lumpectomy
O	211	215	plus
O	216	225	tamoxifen
O	226	228	is
O	229	231	as
O	232	241	effective
O	242	244	as
O	245	255	lumpectomy
O	256	264	followed
O	265	267	by
O	268	277	tamoxifen
O	278	282	plus
O	283	292	radiation
O	293	300	therapy
O	300	301	.

O	302	309	Between
O	310	314	July
O	315	319	1994
O	320	323	and
O	324	332	February
O	333	337	1999
O	337	338	,
O	339	341	we
O	342	350	randomly
O	351	359	assigned
B-total-participants	360	363	636
B-eligibility	364	369	women
I-eligibility	370	373	who
I-eligibility	374	378	were
I-eligibility	379	381	70
I-eligibility	382	387	years
I-eligibility	388	390	of
I-eligibility	391	394	age
I-eligibility	395	397	or
I-eligibility	398	403	older
I-eligibility	404	407	and
I-eligibility	408	411	who
I-eligibility	412	415	had
I-eligibility	416	424	clinical
I-eligibility	425	430	stage
I-eligibility	431	432	I
I-eligibility	433	434	(
I-eligibility	434	440	T1N0M0
I-eligibility	441	450	according
I-eligibility	451	453	to
I-eligibility	454	457	the
I-eligibility	458	463	tumor
I-eligibility	463	464	-
I-eligibility	464	468	node
I-eligibility	468	469	-
I-eligibility	469	479	metastasis
I-eligibility	480	494	classification
I-eligibility	494	495	)
I-eligibility	495	496	,
I-eligibility	497	505	estrogen
I-eligibility	505	506	-
I-eligibility	506	514	receptor
I-eligibility	514	515	-
I-eligibility	515	523	positive
I-eligibility	524	530	breast
I-eligibility	531	540	carcinoma
O	541	548	treated
O	549	551	by
O	552	562	lumpectomy
O	563	565	to
O	566	573	receive
O	574	583	tamoxifen
O	584	588	plus
O	589	598	radiation
O	599	606	therapy
O	607	608	(
B-intervention-participants	608	611	317
O	612	617	women
O	617	618	)
O	619	621	or
B-control	622	631	tamoxifen
I-control	632	637	alone
O	638	639	(
B-control-participants	639	642	319
O	643	648	women
O	648	649	)
O	649	650	.

O	651	658	Primary
O	659	662	end
O	663	669	points
O	670	674	were
O	675	678	the
B-outcome-Measure	679	683	time
I-outcome-Measure	684	686	to
I-outcome-Measure	687	692	local
I-outcome-Measure	693	695	or
I-outcome-Measure	696	704	regional
I-outcome-Measure	705	715	recurrence
O	715	716	,
O	717	720	the
B-outcome-Measure	721	730	frequency
I-outcome-Measure	731	733	of
I-outcome-Measure	734	744	mastectomy
I-outcome-Measure	745	748	for
I-outcome-Measure	749	759	recurrence
O	759	760	,
B-outcome-Measure	761	767	breast
I-outcome-Measure	767	768	-
I-outcome-Measure	768	774	cancer
I-outcome-Measure	774	775	-
I-outcome-Measure	775	783	specific
I-outcome-Measure	784	792	survival
O	792	793	,
B-outcome-Measure	794	797	the
I-outcome-Measure	798	802	time
I-outcome-Measure	803	805	to
I-outcome-Measure	806	813	distant
I-outcome-Measure	814	824	metastasis
O	824	825	,
O	826	829	and
B-outcome-Measure	830	837	overall
I-outcome-Measure	838	846	survival
O	846	847	.

O	848	851	The
O	852	856	only
O	857	868	significant
O	869	879	difference
O	880	887	between
O	888	891	the
O	892	895	two
O	896	902	groups
O	903	906	was
O	907	909	in
O	910	913	the
B-outcome	914	918	rate
I-outcome	919	921	of
I-outcome	922	927	local
I-outcome	928	930	or
I-outcome	931	939	regional
I-outcome	940	950	recurrence
I-outcome	951	953	at
I-outcome	954	958	five
I-outcome	959	964	years
O	965	966	(
B-iv-bin-percent	966	967	1
I-iv-bin-percent	968	975	percent
O	976	978	in
O	979	982	the
O	983	988	group
O	989	994	given
O	995	1004	tamoxifen
O	1005	1009	plus
O	1010	1021	irradiation
O	1022	1025	and
B-cv-bin-percent	1026	1027	4
I-cv-bin-percent	1028	1035	percent
O	1036	1038	in
O	1039	1042	the
O	1043	1048	group
O	1049	1054	given
O	1055	1064	tamoxifen
O	1065	1070	alone
O	1070	1071	,
O	1072	1073	P
O	1073	1074	<
O	1074	1075	0
O	1075	1076	.
O	1076	1079	001
O	1079	1080	)
O	1080	1081	.

O	1082	1087	There
O	1088	1092	were
O	1093	1095	no
O	1096	1107	significant
O	1108	1119	differences
O	1120	1127	between
O	1128	1131	the
O	1132	1135	two
O	1136	1142	groups
O	1143	1147	with
O	1148	1154	regard
O	1155	1157	to
O	1158	1161	the
B-outcome	1162	1167	rates
I-outcome	1168	1170	of
I-outcome	1171	1181	mastectomy
I-outcome	1182	1185	for
I-outcome	1186	1191	local
I-outcome	1192	1202	recurrence
I-outcome	1202	1203	,
I-outcome	1204	1211	distant
I-outcome	1212	1222	metastases
I-outcome	1222	1223	,
I-outcome	1224	1226	or
I-outcome	1227	1231	five
I-outcome	1231	1232	-
I-outcome	1232	1236	year
I-outcome	1237	1242	rates
I-outcome	1243	1245	of
I-outcome	1246	1253	overall
I-outcome	1254	1262	survival
O	1263	1264	(
B-iv-bin-percent	1264	1266	87
I-iv-bin-percent	1267	1274	percent
O	1275	1277	in
O	1278	1281	the
O	1282	1287	group
O	1288	1293	given
O	1294	1303	tamoxifen
O	1304	1308	plus
O	1309	1320	irradiation
O	1321	1324	and
B-cv-bin-percent	1325	1327	86
I-cv-bin-percent	1328	1335	percent
O	1336	1338	in
O	1339	1342	the
O	1343	1352	tamoxifen
O	1353	1358	group
O	1358	1359	,
O	1360	1361	P
O	1361	1362	=
O	1362	1363	0
O	1363	1364	.
O	1364	1366	94
O	1366	1367	)
O	1367	1368	.

O	1369	1379	Assessment
O	1380	1382	by
O	1383	1393	physicians
O	1394	1397	and
O	1398	1406	patients
O	1407	1409	of
O	1410	1418	cosmetic
O	1419	1426	results
O	1427	1430	and
O	1431	1438	adverse
O	1439	1445	events
O	1446	1455	uniformly
O	1456	1461	rated
O	1462	1471	tamoxifen
O	1472	1476	plus
O	1477	1488	irradiation
O	1489	1497	inferior
O	1498	1500	to
O	1501	1510	tamoxifen
O	1511	1516	alone
O	1516	1517	.

O	1518	1528	Lumpectomy
O	1529	1533	plus
O	1534	1542	adjuvant
O	1543	1550	therapy
O	1551	1555	with
O	1556	1565	tamoxifen
O	1566	1571	alone
O	1572	1574	is
O	1575	1576	a
O	1577	1586	realistic
O	1587	1593	choice
O	1594	1597	for
O	1598	1601	the
O	1602	1611	treatment
O	1612	1614	of
O	1615	1620	women
O	1621	1623	70
O	1624	1629	years
O	1630	1632	of
O	1633	1636	age
O	1637	1639	or
O	1640	1645	older
O	1646	1649	who
O	1650	1654	have
O	1655	1660	early
O	1660	1661	,
O	1662	1670	estrogen
O	1670	1671	-
O	1671	1679	receptor
O	1679	1680	-
O	1680	1688	positive
O	1689	1695	breast
O	1696	1702	cancer
O	1702	1703	.
